Lushi Avner 4

What Happened

• Lushi Avner, a director of Silexion Therapeutics Corp (SLXN), was the subject of two awards on Feb 20, 2026: 9,091 restricted share units (RSUs) that were fully vested and immediately settled for underlying ordinary shares, and a separate grant of options covering 10,685 ordinary shares. The reported transaction price for both items is $0.00 and the filing shows no cash paid by the recipient.

Key Details

• Transaction date: 2026-02-20; Form 4 filed: 2026-02-23 (timely within the usual 2-business-day window).
• Reported amounts: 9,091 RSUs (settled to shares) and 10,685 options (derivative award). Reported transaction price for both rows: $0.00.
• Shares owned after the transactions: Not disclosed in the filing.
• Notable footnotes:
  • The RSUs and options were granted to Guangzhou Sino‑Israel Biotech Fund (GIBF) for director services and approved by Silexion’s board.
  • Avner serves as Managing Partner and CEO of GIBF and reports shared voting and investment authority with respect to the securities; he disclaims direct beneficial ownership except to the extent of any indirect pecuniary interest.
  • Options vest in full on the one‑year anniversary of grant approval and expire ten years after grant approval.
• Filing timeliness: Reported with a 3‑day lag from the transaction date but still within the standard Form 4 reporting window.

Context

• RSUs were immediately settled into ordinary shares for GIBF, so the award resulted in underlying shares being issued to the fund rather than a cash transaction or open‑market purchase by the director personally.
• Because the securities were issued to an institutional vehicle (GIBF) and Avner disclaims direct beneficial ownership except for indirect pecuniary interest, this filing documents board‑approved compensation to a fund connected to the director rather than a personal buy or sell that would more directly signal the director’s market view.